

Keep this card with you and show to any healthcare professional involved in your medical care – for example, your pharmacist, GP, emergency doctor or at vaccination clinics.

Your name:

Doctor's name

(who prescribed LEQSELVI):

Doctor's phone number:

The date you started LEQSELVI

LEQSELVI® (deuruxolitinib)



This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See <https://yellowcard.mhra.gov.uk/> or search MHRA Yellow Card in the Google Play or Apple App Store for how to report side effects.

Patient Card

Safety information for patients, or their caregivers, about LEQSELVI:

This card contains important safety information you should be aware of before and during treatment with LEQSELVI

Tell your doctor before starting treatment if you are aged 65 years or older, are a current or past smoker, or have heart or blood vessel problems.

For more information read the patient information leaflet included in each pack of LEQSELVI.

Ask your doctor or pharmacist if any of the information is not clear.

Keep this card with you and show to any healthcare professional involved in your medical care.

What LEQSELVI is and what it is used for

LEQSELVI contains the active substance deuruxolitinib. It is used to treat severe alopecia areata in adults. Alopecia areata is a disease where the body's own immune system attacks hair follicles, causing inflammation that leads to hair loss on the scalp, face and/or other parts of the body.

LEQSELVI works by reducing the activity of enzymes called Janus-associated kinase (JAK), which are involved in inflammation at the hair follicle. This reduces the inflammation, leading to hair regrowth in patients with alopecia areata.

You should know about certain side effects and topics listed in this leaflet, which may be expected because of how the medicine works.

It does not contain all the safety information about this medicine, so you should also read the patient information leaflet supplied with LEQSELVI. It is important to follow the instructions in this booklet and in the patient information leaflet.

Contraception and pregnancy

LEQSELVI must NOT be used during pregnancy.

If you are a woman of childbearing potential, you should use an effective method of contraception during treatment with LEQSELVI. Talk to your doctor about suitable methods of contraception.

Tell your doctor straight away if you become pregnant or think you might have become pregnant during treatment as LEQSELVI can harm the developing baby.

Risk of serious infections

Talk to your doctor or pharmacist before and during treatment with LEQSELVI if you:

- Have an infection (possible signs may be fever, sweating, chills, muscle aches, cough, shortness of breath, blood in your

phlegm, weight loss, diarrhoea, stomach pain, burning when you urinate, urinating more often than usual, feeling very tired)

- Have, or have had, tuberculosis (TB) or have been in close contact with someone with TB, or if you reside or travel in regions where TB is very common.

Your doctor will test you for TB before starting LEQSELVI and may retest you during treatment

- Have ever had a herpes infection (such as chickenpox or shingles), because LEQSELVI may allow it to come back. Tell your doctor if you get a painful skin rash with blisters as this can be a sign of shingles

Vaccines (immunisation)

Talk to your doctor or pharmacist if you have recently had or plan to have a vaccination (immunisation) – this is because certain live vaccines are not recommended immediately before and while using LEQSELVI.

Risk of cancer

Cases of cancer have been reported in patients receiving LEQSELVI. Your doctor will discuss with you if treatment with this medicine is appropriate and whether check-ups, including regular skin checks, will be necessary during treatment.

Risk of gastrointestinal perforations

Seek medical attention immediately if you develop severe or unexplained abdominal pain.

Risk of serious cardiovascular events (heart attack or stroke)

Talk to your doctor before taking LEQSELVI if you have heart problems, have had a heart attack or stroke, or have risk factors such as smoking. During treatment with LEQSELVI, tell your doctor immediately if you develop chest pain or pressure, shortness of breath, or

signs of stroke such as sudden weakness on one side of the body or slurred speech.

Risk of blood clots

Before taking LEQSELVI, talk to your doctor or pharmacist if you have previously had a heart attack, a stroke, blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism), or blood clots in an artery in the eye (retinal occlusion).

During treatment with LEQSELVI, tell your doctor immediately if you get any of the following symptoms:

- A painful swollen leg, warmth or redness in one leg or arm (symptoms of deep vein thrombosis)

- Chest pain or shortness of breath (which may be symptoms of a blood clot in the lungs)
- Any acute changes to your eyesight, such as blurry vision or partial or complete loss of vision (which may be symptoms of a blood clot in an artery in the eye)

Please report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card scheme, via the Yellow Card website at UK:

www.mhra.gov.uk/yellowcard, the free Yellow Card app available in

Apple App Store or Google Play Store. Alternatively you can call

0800 731 6789 for free, Monday to Friday between 9am and 5pm.

By reporting side effects, you can help provide more information on the safety of this medicine.

